Tracers / [99mTc]Tc(CO)3-ADAPT6

[99mTc]Tc(CO)3-ADAPT6

Also written as [Tc-99m]Tc(CO)3-ADAPT6

Radionuclide: Tc-99m t½ 360.6 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

What it is

Compound class: ADAPT scaffold protein (albumin binding domain-derived affinity protein)
Target / mechanism: HER2 (human epidermal growth factor receptor 2) PMID 32998229
Clinical application: —
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	SPE	92.5 ± 1.5%	over 99%	ADAPT6	32998229 2020 Molecules Site-specific radiolabeling of hexahistidine-containing ADAPT6 with [[99mTc]Tc(CO)3]+ to obtain a residualizing label was performed as described earlier — ADAPT6 was radiolabeled with [99mTc]Tc(CO)3 with 92.5 ± 1.5% radiochemical yield and purified to provide a radiochemical purity over 99%

Need this precursor?We can point you to suppliers for [99mTc]Tc(CO)3-ADAPT6, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 32998229. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 32998229: 'ADAPT6'.